James Li, MD
Ophthalmology · Daytona Beach, FLNPI 1396373668
Payments from drug & device makers
What this record shows
Glaukos Corporation accounts for 60.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $1,809 and has fallen 82.1% since, to $323 in 2025.
Across 39 payments — averaging $73.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$360
- Apellis Pharmaceuticals, Inc.$259
- AbbVie$126
- Bausch & Lomb Americas Inc.$123
- Astellas Pharma US Inc$86
- plus $182 from 4 others
Across 2 payments — averaging $8000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$16K
What the payments were for
- Travel & lodging$1,27745%
- Food & beverage$1,58955%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 5 | $1,731 |
| Alcon | 17 | $360 |
| Apellis Pharmaceuticals, Inc. | 2 | $259 |
| AbbVie | 1 | $126 |
| Bausch & Lomb Americas Inc. | 6 | $123 |
| Astellas Pharma US Inc | 1 | $86 |
| Dompe US, Inc. | 3 | $85 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,867 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $11,643 |
| Prednisolone Acetate | 42 | $1,375 |
| Latanoprost | 95 | $949 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 41 | $711 |
| MoxifloxacinMoxifloxacin Hcl | 23 | $628 |
| ErythromycinErythromycin Base | 41 | $447 |
| Timolol Maleate | 27 | $347 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $231 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Daytona Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.